Filed Pursuant to Rule 424(b)(5)
Under the Securities Act of 1933
Registration No. 333-233822
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to Completion, dated February 18, 2020
PROSPECTUS SUPPLEMENT
(To Prospectus dated September 18, 2019)
4,000,000 Shares
![LOGO](https://capedge.com/proxy/424B5/0001193125-20-040316/g873052g22z36.jpg)
Common Stock
We expect to enter into forward sale agreements (collectively, the “forward sale agreements”) with an affiliate of J.P. Morgan Securities LLC, an affiliate of Barclays Capital Inc., an affiliate of BofA Securities, Inc. and an affiliate of Wells Fargo Securities, LLC, which affiliates we refer to in such capacity as the “forward purchasers,” with respect to an aggregate of 4,000,000 shares of our common stock. In connection with these forward sale agreements, the forward purchasers or their respective affiliates, whom we refer to in such capacity as the “forward sellers,” at our request, are borrowing from third parties and selling to the underwriters an aggregate of 4,000,000 shares of our common stock.
We will not receive any proceeds from the sale of shares of our common stock by the forward sellers to the underwriters. We currently expect to fully physically settle the forward sale agreements and receive cash proceeds, subject to certain adjustments pursuant to the forward sale agreements, upon one or more settlement dates within approximately one year from the date of this prospectus supplement. If we elect to cash settle all or a portion of our obligations under the forward sale agreements, we may not receive any proceeds from such election, and we may owe cash to the forward purchasers. If we elect to net share settle all or a portion of our obligations under the forward sale agreements, we will not receive any cash proceeds from such election, and we may owe shares of our common stock to the forward purchasers. See “Underwriting (Conflicts of Interest)—Forward Sale Agreements.”
A forward seller is not required to borrow shares if, after using commercially reasonable efforts, it is unable to borrow such shares, or if borrowing costs exceed a specified threshold or if certain conditions specified in the underwriting agreement have not been satisfied. If any forward seller does not deliver and sell all of the shares of our common stock to be delivered and sold by it, we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares that such forward seller does not deliver and sell, and the number of shares underlying the relevant forward sale agreement will be decreased by the number of shares that we issue and sell.
Our common stock is listed on the New York Stock Exchange, or “NYSE”, under the symbol “KRC.” The last reported sale price of our common stock on the NYSE on February 14, 2020 was $88.28 per share.
Shares of our common stock are subject to certain restrictions on ownership and transfer designed to preserve our qualification as a real estate investment trust for federal income tax purposes. See “Description of Capital Stock—Restrictions on Ownership and Transfer of the Company’s Capital Stock” in the accompanying prospectus.
An investment in our common stock involves various risks and prospective investors should carefully consider the matters discussed under “Risk Factors” beginning onpage S-9 of this prospectus supplement and the matters discussed in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus before making a decision to invest in our common stock.
| | | | | | | | |
| | Per Share | | | Total | |
Public offering price | | $ | | | | $ | | |
Underwriting discounts and commissions | | $ | | | | $ | | |
Proceeds, before expenses, to Kilroy Realty Corporation(1) | | $ | | | | $ | | |
(1) | We currently expect to fully physically settle the forward sale agreements (by the delivery and sale of shares of our common stock to the forward purchasers) and receive cash proceeds, subject to certain adjustments pursuant to the forward sale agreements, upon one or more settlement dates within approximately one year from the date of this prospectus supplement. Except in certain circumstances, we also have the right to elect cash settlement or net share settlement under the forward sale agreements. Assuming full physical settlement of the forward sale agreements at an initial forward sale price of $ per share (which is equal to the public offering price per share less the underwriting discounts and commissions per share as set forth on the table above), we would expect to receive net proceeds of approximately $ million, or approximately $ million if the underwriters exercise their option to purchase additional shares in full, in each case after deducting discounts and commissions and estimated expenses payable by us related to the forward sale agreements and this offering, subject to certain adjustments pursuant to the forward sale agreements. See “Underwriting (Conflicts of Interest)—Forward Sale Agreements” for a description of the forward sale agreements. |
The forward sellers have granted the underwriters an option to purchase up to 600,000 additional shares of our common stock exercisable in whole or in part at any time and from time to time through and including the 30th day after the date of this prospectus supplement. Upon any exercise of such option, the total number of shares of our common stock underlying each forward sale agreement will be increased by the number of shares delivered and sold by the applicable forward seller in respect of such option exercise. A forward seller is not required to borrow shares for delivery upon exercise of such option by the underwriters if, after using commercially reasonable efforts, it is unable to borrow such shares, or if borrowing costs exceed a specified threshold or if certain conditions specified in the underwriting agreement have not been satisfied. If any forward seller does not deliver and sell all of the shares of our common stock to be delivered and sold by it in connection with the exercise of such option, we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares that such forward seller does not deliver and sell, and the number of shares underlying the relevant forward sale agreement will not be increased in respect of the number of shares that we issue and sell.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
We expect that the shares of common stock will be ready for delivery through The Depository Trust Company on or about , 2020.
Joint-Book Running Managers
| | | | | | |
J.P. Morgan | | Barclays | | BofA Securities | | Wells Fargo Securities |
Prospectus Supplement dated , 2020